10 Stocks Investors Are Dumping Right Now

Page 3 of 3

4. USA Rare Earth Inc. (NASDAQ:USAR)

USA Rare Earth dropped its share price by 12.62 percent on Monday to end at $7.13 apiece after receiving a rating downgrade from William Blair over feedstock shortages.

In a market note, the investment firm lowered its stock rating for USA Rare Earth Inc. (NASDAQ:USAR) to market perform from outperform previously on the belief that it is likely to face near-term challenges, including recent feedstock shortages that are slowing rare earth magnet production.

Additionally, William Blair underscored USA Rare Earth Inc.’s short track record as a publicly listed company and warned against investing in a company that has yet to demonstrate the ability to ramp up production to its full potential.

Despite the downgrade, USA Rare Earth Inc. still holds a strong buy rating across six analysts covering the stock, five of which recommended buying its shares, while one said to hold.

This month alone, Northland Securities, Roth MKM, and Cantor Fitzgerald all reiterated their buy recommendations on the mining firm’s stock, albeit lowering their price targets to a range of $20 to $30 from $30 to 45 prior.

In other news, USA Rare Earth Inc. announced that the start of shipping of mixed rare earth carbonate to US SIIE, LLC—a special purpose vehicle funded by the US government. It also began receiving payments this month.

The shipment forms part of a 15-year take-or-pay offtake agreement providing for the sale of products derived from Serra Verde’s Phase 1 production to US SIIE, including neodymium (Nd), praseodymium (Pr), dysprosium (Dy) and terbium (Tb).

3. GDS Holdings Ltd. (NASDAQ:GDS)

GDS Holdings Ltd. (NASDAQ:GDS) fell by 14.69 percent on Monday to finish at $16.90, mimicking a broader decline in the US markets, dampened by uncertainties surrounding Nvidia Corp. and its impact on the broader artificial intelligence sector.

Considered the bellwether of the global AI infrastructure buildout, Nvidia’s fall to record lows last week spilled over to related technology stocks amid concerns about the industry’s growth trajectory.

Investors also positioned portfolios ahead of Nvidia Corp.’s earnings release after market close on Tuesday, November 17, which is expected to shed light on its leadership composition following Jensen Huang’s resignation, alongside its updated outlook over the short-term period.

For its part, GDS Holdings Ltd. is set to announce the results of its earnings performance for the third quarter of the year before market open on November 25. A conference call will be held to elaborate on the results.

In its last earnings call, GDS Holdings Ltd. guided a full-year total revenue outlook of RMB 12.7 billion to RMB 13 billion, or an upgrade from the RMB 12.4 billion to RMB 12.9 billion expected in the first quarter of the year.

2. Icahn Enterprises LP (NASDAQ:IEP)

Icahn Enterprises fell by 15.09 percent on Monday to close at $3.6 apiece, as investors disposed of its shares following the ex-date for its next dividend payment.

It can be recalled that the company’s board of directors approved the distribution of $0.50 in dividends to all depositary unit holders of November 16 record, payable on December 23. The dividends form part of Icahn Enterprises LP’s (NASDAQ:IEP) quarterly dividends.

The distribution announcement followed Icahn Enterprises LP’s earnings results in the third quarter of the year, where it swung to an attributable net loss of $225 million from a $287 million net income in the same period last year amid refining hedges in the investment funds attributable to the company.

Revenues, on the other hand, increased by 16 percent to $3.17 billion from $2.7 billion year-on-year, with net sales contributing to the bulk at $3.549 billion, or 53 percent higher than the $2.3 billion year-on-year.

However, the higher net sales were offset by losses from investment activities, at $779 million versus $48 million in the same comparable period.

Adjusted EBITDA attributable to the company ended at a loss of $214 million, as compared with a $75 million adjusted EBITDA year-on-year.

1. Summit Therapeutics Inc. (NASDAQ:SMMT)

Summit Therapeutics fell for a 5th straight day on Monday to touch a new 52-week low after the Food and Drug Administration (FDA) thumbed down its Biologics License Application (BLA) for its lung cancer treatment candidate, Ivonescimab, amid the lack of substantial evidence in overall survival data.

In intraday trading, the stock nosedived to a record low of $11.54 before paring losses to end the day down by 16.47 percent at $11.82 apiece.

Summit Therapeutics Inc. (NASDAQ:SMMT) said that the FDA rejected its BLA after determining that substantial evidence of effectiveness was not established amid the absence of a statistically significant improvement in enrolled patients’ overall survival.

Additionally, the FDA indicated that data on progression-free survival (PFS) without any improvement in overall survival do not support a positive benefit-risk profile.

The BLA was based on Summit Therapeutics Inc.’s data from its double-blind Phase 3 clinical trial, which aimed to study Ivonescimab in combination with chemotherapy, where PFS—its primary endpoint—was met.

The study found that Ivonescimab combined with chemotherapy was well-tolerated with no new safety signals and comparable rates of discontinuation and death.

However, 16 patients in the Ivonescimab group and 11 patients in the placebo group discontinued due to adverse effects.

Nine patients died, including four from the Ivonescimab plus chemotherapy arm group, and five in the chemotherapy alone.

“We are disappointed for patients and their families awaiting additional treatment options in this setting,” Chairman and CEO Robert Duggan said.

“With five positive Phase 3 studies between Summit and Akeso, nothing changes with respect to our ever-growing belief in the opportunity for Ivonescimab and our determination to advance Ivonescimab’s development. Our mission remains to improve outcomes for patients facing significant unmet needs, which is work worth doing, and we will continue through our expansive clinical development program,” he noted.

READ NEXT: Forget Nvidia: 10 Stocks Wall Street is Betting on Right Now and Buy Alert: 10 Stocks Analysts Upgraded on Friday

Follow Insider Monkey on Google News.

Page 3 of 3